RealTime Dynamix™: Renal Anemia, June 2016
Monthly report covering the dialysis and chronic kidney disease market for ESAs and IV Iron. Additional insight on the development pipeline including receptivity to biosimilar ESAs and growing awareness of a novel class of anemia agents, the HIF-PH inhibitors. n=104 nephrologists
Download Report Overview
About Spherix Global Insights
Spherix Global Insights is a newly established business intelligence and market research company headquartered in Cambridge, MA with EU offices in Zug, Switzerland. We specialize in renal, autoimmune, neurologic and rare disease markets.
For more information contact:
Telephone: (800) 661-0571
Email: info@spherixglobalinsights.com
www.spherixglobalinsights.com
Related Posts
-
Janssen’s Stelara overtakes Takeda’s Entyvio as the leading alternative MOA in Crohn’s Disease, but pressure is on to maximize IBD value in advance of pipeline drugs from Celgene (mongersen, ozanimod), Roche/Genentech (etrolizumab) and Pfizer (Xeljanz)
According to RealWorld Dynamix: Biologic Switching in IBD, an annual patient chart analysis conducted by Spherix Global Insights, biologic use…
-
FDA Approval of Mylan’s Glatiramer Acetate Will Turn the Payer Pressure On for Teva’s Copaxone and Sandoz’s Glatopa
While Copaxone brand loyalists and therapeutic equivalence concerns remain, the preference for three-times-weekly dosing will diminish reluctance to initiate generics,…
-
NEPHROLOGISTS PERCEIVE THE ANEMIA EFFECTS OF KERYX’S AURYXIA TO BE FAVORABLE, BUT MARKET PENETRATION AT SIX MONTHS POST LAUNCH IS LOW
Familiarity with Auryxia is the primary barrier to adoption and growth, according to Spherix Global Insights, GmbH August 20, 2015…
